Immuron Limited (IMRN)

Market Cap	15.18M
Revenue (ttm)	2.43M
Net Income (ttm)	-2.64M
Shares Out	6.25M
EPS (ttm)	-0.44
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,416
Open	2.420
Previous Close	2.580
Day's Range	2.370 - 2.430
52-Week Range	1.481 - 5.960
Beta	1.14
Analysts	n/a
Price Target	n/a
Earnings Date	May 7, 2024

About IMRN

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1994
• Employees: 6
• Stock Exchange: NASDAQ
• Ticker Symbol: IMRN

Financial Performance

In 2023, Immuron's revenue was 1.80 million, an increase of 135.85% compared to the previous year's 765,193. Losses were -3.79 million, 32.7% more than in 2022.

Financial numbers in AUD